NOD2 mutations and anti-Saccharomyces cerevisiae antibodies (ASCAs) are established risk factors of Crohn ' s disease (CD) in whites but have not been assessed in African-American (AA) adults with CD.
INTRODUCTION
Crohn ' s disease (CD) is a chronic, infl ammatory bowel disease (IBD) that primarily involves the ileum and / or colon.
Underscoring the phenotypic heterogeneity of CD, previous studies have identifi ed CD phenotypes with distinct clinical features (such as age at diagnosis, site of involvement, and NOD2 Mutations and Anti-Saccharomyces cerevisiae Antibodies Are Risk Factors for Crohn ' s Disease in African Americans family history), complications (infl ammatory, stricturing, and / or penetrating behavior), and need for surgery (1 -4) .
Th ree NOD2 mutations (Leu1007fs / 3020insC (Leu1007fsinsC), G908R / 2722g>c, and R702W / 2104c>t), found commonly in all European ancestry populations (7 -19 % carriers in controls vs. 16 -45 % in CD cases in hospital-based studies), were the fi rst to be identifi ed and remain the highest penetrance genetic risk factors for CD in white populations (5 -7) . NOD2 -associated overall risk was 2.4-fold for simple heterozygotes and 17-fold for homozygote / compound heterozygote mutation carriers (7) . NOD2 mutations have also been associated with the following specifi c CD phenotypes: younger age at disease onset (8 -11) , ileal involvement (8,9,11 -15) , and complicated (stricturing and penetrating) behavior (8,10 -12,16,17) . Interestingly, the expression of antibodies to Saccharomyces cerevisiae (ASCA) has been associated with a CD phenotype that is remarkably similar to that of patients with NOD2 polymorphisms. ASCAseropositive patients present at a younger age (18 -23) and are more likely to have ileal disease (18 -25) . Th ey are also at greater risk for complicated disease behavior (18,21,24 -27) and require surgery more frequently (21, 24, 26, 28) .
Our group reported a dose response between the number of NOD2 mutations and the prevalence and titers of ASCA (18) , a fi nding that was also reported in studies from Italy (11) and Hungary (29) . Importantly, we also found that the ASCA titer was associated with ileal involvement and complicated behavior, independently of NOD2 status (18) .
To date, there have been no studies of ASCA in the AfricanAmerican (AA) population. Th e only study of NOD2 in AAs was in children and found that NOD2 alleles were infrequent in AA children with CD in comparison with white children with CD (allele frequency 1.6 vs. 25.7 % , P < 0.0001) (30) . NOD2 mutations showed equal frequencies among 58 AA children with CD relative to 124 controls (heterozygote carriers 3.8 vs. 4.3 % , respectively). However, the study was not adequately powered to assess the risk of NOD2 , given the low frequency of NOD2 mutations and low risk of heterozygotes, and controls were taken from newborn screening dried blood spots. We along with others have observed that AA patients with CD have lower frequencies of an IBD family history (30 -34) and ileal involvement (31, 35) than do white CD patients. In view of the biological and genetic heterogeneity of CD, as well as the diff erences in the CD phenotype in AA patients, we conducted a study to characterize ASCA and three common NOD2 mutations in CD in the AA population.
METHODS

Patient population
Th e study population consisted of 334 individuals, self-identifi ed as AAs and recruited between 2003 and 2007 by the MAAAIS (Mid-Atlantic African-American Infl ammatory Bowel Disease Study), which is a substudy of the IBDGC (Infl ammatory Bowel Disease Genetics Consortium) (31) . Th e study comprised 190 unrelated patients who carried a diag nosis of CD, and 144 matched, healthy controls. Blood samples for DNA purifi cation and sera were successfully collected from all study subjects. We included all study subjects available at this time. Th e MAAAIS is coordinated through the Meyerhoff IBD Center at the Johns Hopkins University with recruitment from the Meyerhoff IBD Center clinics, the Johns Hopkins Hospital, and from satellite recruitment at the IBD centers at Howard University, University of Florida, University of North Carolina, University of Pennsylvania, and the Washington Hospital Center (Washington, DC). Subjects were also referred to the Johns Hopkins coordinating site by their gastroenterologists in the State of Maryland or by the Maryland, Washington, and Northern Virginia Chapter of the CCFA (Crohn ' s and Colitis Foundation of America), or were self-referred aft er learning about the study from Institutional Review Board-approved advertisements for AA patients and AA healthy controls in newspapers of the Baltimore area. Healthy controls were the nongenetically related spouse, partner, or friend of the case, and were without a known personal or family history of IBD. Th e controls were recruited by each center primarily by referral from cases. When cases were unable to refer a control, population controls living in the same geographic region (i.e., identical fi rst three digits of mail " zip " code) and matched by age and sex were also recruited. An additional 26 CD cases and 13 controls were also included who were unrelated AA participants of the Meyerhoff IBD Center genetics research studies between 1997 and 2003 and who had both sera and DNA.
AA ethnicity was self-defi ned. In addition, as part of a separate study, we had genotyped 96 African -European admixture informative markers in comparison with West-African and European controls, and average ethnicity was identical between cases and controls (78.9 vs. 80.2 % average West-African ancestry, respectively) (36) . One of the controls had 98 % European ancestry and was excluded. None of the remaining participants had < 28 % West-African ancestry. Diagnosis of CD was confi rmed by chart review, in accordance with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) IBDGC requirements (31) .
DNA samples were successfully isolated in 100 % of study subjects. DNA was purifi ed from blood using a Gentra Puregene Kit (Qiagen, Valencia, CA). Samples obtained from cases and controls were plated for genotyping or serotyping together, and laboratory personnel were blinded to disease status. In each genotyping plate, water controls were used to control for cross-sample contamination and samples of known genotypes and duplicate samples (placed in wells on two diff erent plates), were placed as negative and positive controls.
Phenotyping
CD phenotyping was performed using a previously validated protocol and in accordance with the Montreal Classifi cation (37, 38) . Age at diagnosis was determined by chart review and if necessary by patient questionnaire. For disease location, patients were classifi ed into one of four mutually exclusive groups: (i) L1: ileum involvement only, (ii) L2: colonic involvement only, (iii) L3: ileocolonic involvement, and (iv) L4: isolated upper
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gastrointestinal involvement. Disease location was determined as maximal extent of the disease. As specifi ed in the Montreal Classifi cation, perianal and rectovaginal fi stulae did not, by themselves, constitute penetrating disease. History of surgery was confi rmed bowel resection or diversion for treatment of CD or related complications. History of immunomodulator use was defi ned as any history, captured in the medical records, or as reported by the patient, of azathioprine, 6-mercaptopurine, or methotrexate use. History of infl iximab use was infl iximab therapy as reported in the medical records or by the patient. Family history of CD was defi ned as CD in a fi rst-or second-degree relative (such as a parent, sibling, grandparent, or an avuncular relative). Current smoking was defi ned as consumption of a minimum of seven cigarettes per week for at least 1 year.
NOD2 genotyping
Patients were genotyped for Leu1007fsinsC and G908R / 2722g>c polymorphisms using the TaqMan method as described previously (39) . R702W / 2104c>t status was determined by PCR amplifi cation of NOD2 exon 4, column purification, and direct sequencing.
ASCA
Sera were analyzed for the presence of S. cerevisiae IgG and IgA antibodies using a commercially available enzyme-linked immunosorbent assay according to the manufacturer ' s specifications (Quanta Lite, INOVA Diagnostics, San Diego, CA). Th e test result is calculated by multiplying the ratio of sample to control optical density with the number of units assigned to the control by the manufacturer. Reactivity is related to the quantity of antibody present in a nonlinear manner. Results are classifi ed as negative (0.0 -20.0 Units), equivocal (20.1 -24.9 Units), and positive ( ≥ 25 Units). Our ASCA assay correlates well with the assay of Prometheus Laboratories (San Diego, CA), which is the most commonly used assay in the United States (40) .
Statistical analysis
Statistical analysis was conducted using Stata 10 (StataCorp LP, College Station, TX). Patients were considered ASCA + if they were ASCA IgA-positive (ASCA IgA + ) and / or ASCA IgG-positive (ASCA IgG + ). As stricturing and penetrating behaviors represent more complicated disease that almost always necessitates surgery, we jointly analyzed these patients, as we did in our previous study of white CD patients (18) .
Patient genotypes were divided into three groups, namely " MM, " patients carrying two NOD2 mutant alleles (homozygotes or compound heterozygotes); " MW, " those carrying a single NOD2 mutant allele and a single wild type allele; and " WW, " those carrying only wild-type alleles.
Th e prevalence rates of ASCA in the CD and control populations were compared using the χ 2 statistic. Characteristics of ASCA + and ASCA -patients were compared using the Wilcoxon rank-sum test for continuous variables, and the χ 2 or Fisher ' s exact test for nominal categorical variables. Th e prevalence rates of NOD2 mutations and NOD2 allele frequencies in CD cases and controls were compared using the Fisher exact test. Population attributable risk in AAs was calculated according to the study by Schlesselman (41) as follows: population attributable risk = [Pe × (OR − 1)] / [Pe × (OR − 1) + 1], where Pe is the prevalence of exposure ( NOD2 mutation) in the population and OR the odds ratio for CD and any NOD2 mutation.
Th e independent association between ASCA titer and other factors with the presence of ileal involvement and stricturing / penetrating behavior was evaluated with logistic regression aft er adjusting for disease duration, age at diagnosis, family history, and smoking at the time of diagnosis. We used Cox proportional hazards to assess the association between the ASCA titer and time to surgery while adjusting for the same covariates used for the logistic regression models. Disease behavior was not included in the model for disease site, as disease behavior evolves over time. Disease behavior was also not included in the model for time to surgery, as disease behavior is frequently determined near or at the time of surgery.
Ethical considerations
Th e Institutional Review Boards of the Johns Hopkins Medical Institutions, the University of North Carolina, the University of Pennsylvania, Washington Hospital Center, the University of Florida and Howard University approved the study, and informed consent was obtained from all patients.
RESULTS
Patient characteristics
Among the 190 unrelated AA patients recruited who carried a diagnosis of CD on the basis of their physicians ' assessment, our review of primary medical records confi rmed a diagnosis of CD in 183 cases (with 1 case reclassifi ed as indeterminate colitis). Aft er exclusion of 1 control who had < 15 % West-African ancestry, there were 143 controls. Th e characteristics of these studied CD cases and controls are presented in Table 1 . Th e mean (s.d.) age of patients at diagnosis was 27.1 (12.9) years. A family history of IBD was observed in 11.5 % of patients. Ileal involvement (isolated ileal or ileocolonic) was seen in 66.0 % . Disease behavior was infl ammatory in 45.0 % , stricturing in 30.8 % , and penetrating in 24.2 % of the patients. Immunomodulators and infl iximab were used in 62.8 and 42.8 % of patients, respectively.
ASCA
Among the 183 AA patients with CD, 129 (70.5 % ) were ASCA + . ASCA data were available for 142 controls. Among the controls, 100 were ASCA -, yielding an ASCA specifi city of 70.4 % for CD. Age at diagnosis was signifi cantly lower in ASCA + patients (25.0 ± 11.8 vs. 32.1 ± 14.2, P < 0.001) ( ( Table 2 ). We found no association between any NOD2 mutation and ileal involvement or CD behavior. In addition, no association was observed between individual mutations and any phenotypic characteristics (data not shown). However, with so few NOD2 cases, we had limited power to identify very strong eff ects.
Multivariate analysis
We evaluated the independent association of the ASCA titer as a continuous variable with ileal (L1 or L3) involvement using multiple logistic regression ( Table 3 ). Ileal involvement was independently associated with the ASCA titer (OR 1.18 per 25-Unit increase, 95 % CI: 1.04 -1.34, P = 0.01) aft er adjustment for age at diagnosis, disease duration, family history, and smoking.
Both stricturing and penetrating behaviors are encountered more frequently in patients with ileal disease. Th erefore, we investigated whether the association between ASCA and complicated behavior persisted aft er accounting for the contribution of ileal involvement. On multiple logistic regression ( Table 4 ) , the ASCA titer was associated with complicated behavior (OR 1.13 per 25-Unit increase, 95 % CI: 1.01 -1.27). In addition, complicated disease behavior was independently associated with ileal involvement (OR: 3.97, 95 % CI: 1.84 -8.54) and longer disease duration (OR: 1.75 per 10 years, 95 % CI: 1.11 -2.75). Table 5 shows the results of the analysis of time to surgery. Shorter time to surgery was associated with ASCA titer (hazard ratio: 1.11 per 25-Unit increase, 95 % CI: 1.02 -1.22), family history of CD (hazard ratio: 2.39, 95 % CI: 1.11 -5.14), and smoking (hazard ratio: 1.50; 95 % CI: 1.14 -1.99). 
DISCUSSION
Our study is the fi rst to assess ASCA and the three common NOD2 mutations in AA adults with CD. We report the following fi ndings: (i) Th e sensitivity of ASCA for CD in AAs was 70.5 % ; (ii) Th e specifi city of ASCA for CD was 70.4 % ; (iii) ASCA was independently associated with earlier disease onset, ileal involvement, complicated behavior, and surgery; and (iv) Although less common than in whites, the presence of a NOD2 mutation, and specifi cally that of Leu1007fsinsC, was for the fi rst time shown to be a risk factor for CD in AAs. In a previous study (31) , we found that AA adult patients with CD were signifi cantly more likely than whites to develop upper gastrointestinal disease (OR, 2.8), colorectal involvement (OR, 1.9), perianal disease (OR, 1.7), and particularly extraintestinal manifestations of uveitis and sacroileitis (OR, 5.5 and OR, 4.0, respectively). Conversely, AA patients were less likely to have ileal involvement (OR, 0.55) or internal penetrating disease (OR, 0.59). A family history of IBD was present less frequently in AA than in their White counterparts (20 vs. 31 % , P < 0.05). Other studies have also found diff erences in CD family history and phenotypic manifestations by race (30,32 -35) . Diff erences between white and AA CD patients in terms of family history, disease location, and extraintestinal manifestations suggest potential genetic and environmental diff erences.
Numerous studies have linked CD phenotypes with genetic polymorphisms. NOD2 mutations have been associated with ileal involvement and complicated behavior (8 -10,12 -17) . Although NOD2 is a confi rmed CD susceptibility gene in white populations, NOD2 mutations are rare or absent among other ethnic groups (42 -44) . To date, only one study in a population from Wisconsin, USA, has assessed NOD2 mutations in the AA population (30) . In that report, NOD2 allele frequencies were markedly lower in AA than in white children, both among healthy controls (2.1 vs. 9.1 % , P < 0.01) and among CD patients (1.6 vs. 25.7 % , P < 0.0001). Th ere was no observed association between NOD2 and CD in the AA children. Yet, given the small size (58 cases and 124 controls) and the low NOD2 mutation frequency in the AA population, the study was underpowered to observe the overall three-fold risk observed in NOD2 mutation carriers seen in European ancestry studies (7) . For example, a meta-analysis of 29 non-Jewish, white, hospital-based studies reported a NOD2 risk of 3.2 (95 % CI: 2.8 -3.6) for all NOD2 carriers, with OR 2.4 (95 % CI: 2.0 -2.9) for simple heterozygotes (MW) and 17.1 (95 % CI: 10.7 -27.2) for two mutant allele carriers (MM) (7) . NOD2 risk in our study (OR for heterozygotes 4.17, 95 % CI: 1.18 -14.69) was therefore within the same range. Nonetheless, the lower frequency of NOD2 in the AA population relative to white populations results in a much smaller population attributable risk, only 6.2 % in AA vs. 22 % in non-Jewish whites (7) .
We did not observe any NOD2 mutant homozygotes or compound heterozygotes, and given the low NOD2 mutation allele frequency in both ours and the wisconsin AA controls, (assuming Hardy -Weinberg equilibrium) only 0.01 -0.04 % of AA individuals would be expected to be NOD2 homozygotes, as compared with the 0.5 % of whites observed in a large study (45) . It should be noted that the three NOD2 mutations are assumed to occur only in the European admixture. R702W and G908R mutations were not present in 118 chromosomes genotyped in the Yoruban population (HapMap YRI database). Recently, Gasche et al. (46) genotyped the three NOD2 mutations in DNA from seven sub-Saharan African populations (including 25 Yorubans) and did not identify any NOD2 mutations, including Leu1007fsinsC. In a study of 3,575 healthy whites from around the world, NOD2 mutant allele frequency was reported to be 7.8 % (45) . European -African admixture among the AA population has been considered as a continual process for more than four centuries, and the presence of NOD2 mutations may be aff ected by survival advantages and disadvantages. For example, NOD2 mutations may produce a survival advantage to exposure to certain infectious pathogens (46, 47) . Th e 1.1 % NOD2 mutant allele frequency observed among AA controls is lower but within error of that expected from the 20 % overall white admixture in AAs. It will be important to conduct larger studies of NOD2 in AA CD cases and healthy controls to (i) better defi ne the overall AA population risk of NOD2 mutations; (ii) assess whether NOD2 mutations in the AA population are less frequent than expected by overall white admixture; and (iii) determine whether the low rate of NOD2 mutations indeed explains the lower frequency of ileal CD in AAs.
With regard to individual mutations, only Leu1007fsinsC was signifi cantly associated with CD. Th e frequency of this mutation was 1.9 % in patients vs. 0 % in controls ( P = 0.02). In a meta-analysis of European ancestry studies, Economou et al. (7) also observed that carriers of the Leu1007fsinsC mutation had a risk (OR 4.1; 95 % CI: 3.2 -5.2) signifi cantly greater than carriers of the R702W allele (OR 2.2; 95 % CI: 1.8 -2.6), and a trend toward a greater risk than carriers of the G908R allele (OR 3.0; 95 % CI: 2.4 -3.7). As in nearly all NOD2 studies, we observed that the G908R and R702W allele frequencies were numerically greater in CD than in controls (R702W: 1.6 vs. 1.1 % ; G908R: 0.5 vs. 0.0 % ), but the diff erences did not reach statistical signifi cance. It must be noted that we had only 30 % power to observe a signifi cant association for the presence of any NOD2 mutation, given the overall mutant allele frequency of 0.010 in AA controls, and assuming the meta-analysis NOD2 risks observed in whites. Th erefore, much larger studies will be required to assess the risk of the individual alleles. NOD2 mutations were not a risk factor for ileal disease or complicated disease in the AA population, but again the study was underpowered. ASCA expression has been associated in white populations with ileal involvement, earlier age at onset, stricturing and penetrating CD, and need for surgery (18 -28) . Furthermore, we found that the ASCA titer was associated with complicated behavior independent of NOD2 status and ileal involvement. However, it is not known whether ASCA retains its phenotypic associations in AAs with CD, a population with a lower frequency of NOD2 mutations and, probably, a diff erent disease phenotype. Using the cutoff values determined by the manufacturer, the sensitivity and specifi city values of our ASCA assay (Quanta Lite) in the AA CD population were 70.5 and 70.4 % respectively. In comparison, the sensitivity of the Quanta Lite assay in whites ranged between 48 and 76 % (18, 22, 48, 49) . Assay specifi city was somewhat lower than the values observed in whites (86 -89 % ) (40, 48, 49) . Th ese diff erences should be placed in perspective by recognizing the fact that the diagnostic accuracy of a test depends on the spectrum of diseased and nondiseased individuals comprising the study populations. As in whites, ASCA was associated with earlier disease onset, ileal involvement, complicated behavior, and surgery in AA patients as well. On multivariate analysis, the ASCA titer remained associated with ileal involvement, complicated behavior, and surgery. In this study, ASCA was not associated with NOD2 mutations in AA, but there was a small number of NOD2 carriers. ASCA seroprevalence is similar in whites and AAs, whereas NOD2 mutations are much less common in AAs compared with whites. Th erefore, other genes may be associated with the generation of ASCA in AAs.
In summary, ASCA in AAs was associated with CD diagnosis, earlier disease onset, ileal involvement, complicated behavior, and surgery. In the AA population, the Leu1007fsinsC NOD2 mutation was associated with CD diagnosis. However, NOD2 mutations, the strongest genetic risk factors identifi ed for CD, account for a much smaller proportion of CD among the AA population than among white populations. Nonetheless, the incidence of CD in both populations in the United States has been found to be similar (50) . Th erefore, further studies are required to assess the importance of other CD risk genes in AA and to identify specifi c novel genetic and potential environmental risk factors in this understudied American population.
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